Skip to content
lifestyle.capitolhilltimes.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Outlook Therapeutics, Inc.
Outlook Therapeutics Announces Pricing of $5.0 Million Public Offering
March 24, 2026
Outlook Therapeutics Announces Proposed Public Offering
March 23, 2026
Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA™ (bevacizumab gamma) in Switzerland
February 19, 2026
Outlook Therapeutics Submits Type A Meeting Request to FDA Following Complete Response Letter
February 12, 2026
←
Previous Page
1
2
3